|
Enamine Ltd
5s 4 5s 4, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/AMG-510/pmc08041284__ja0c10644_si_002-2-2-8 Average 93 stars, based on 1 article reviews
5s 4 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
MedChemExpress
amg 510 ![]() Amg 510, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/Sotorasib/pmc08296985-34-0-2 Average 96 stars, based on 1 article reviews
amg 510 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
MedChemExpress
sotorasib amg510 ![]() Sotorasib Amg510, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/Sotorasib/pmc10920083-38-0-5 Average 95 stars, based on 1 article reviews
sotorasib amg510 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
TargetMol
sotorasib ![]() Sotorasib, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/Sotorasib/pmc13486645-271-0-5 Average 95 stars, based on 1 article reviews
sotorasib - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Selleck Chemicals
amg510 ![]() Amg510, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/Sotorasib+(AMG510)+racemate/pmc07549316-359-2-6 Average 93 stars, based on 1 article reviews
amg510 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Amgen
amg 510 ![]() Amg 510, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/amg+510/pmc07041424-191-0-3 Average 90 stars, based on 1 article reviews
amg 510 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
AbMax Inc
pan anti-amg510 antibody ![]() Pan Anti Amg510 Antibody, supplied by AbMax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/pan+anti+amg510+antibody/pmc09942120-212-1-7 Average 90 stars, based on 1 article reviews
pan anti-amg510 antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
AbMole Bioscience
amg510 m9356 ![]() Amg510 M9356, supplied by AbMole Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/amg510+m9356/pmc09942120-198-0-8 Average 90 stars, based on 1 article reviews
amg510 m9356 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Deciphera Pharmaceuticals
amg510 ![]() Amg510, supplied by Deciphera Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/amg510/10__1158_slash_0008___5472__can___22___0391-68-0-4 Average 90 stars, based on 1 article reviews
amg510 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Mirati Therapeutics
sotorasib (amg510) ![]() Sotorasib (Amg510), supplied by Mirati Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/amg510/10__1096_slash_fj__202401734r-78-13-81 Average 90 stars, based on 1 article reviews
sotorasib (amg510) - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
BeiGene Inc
amg510 kras inhibitor ![]() Amg510 Kras Inhibitor, supplied by BeiGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/amg510+kras+inhibitor/pmc10807637-51-3-6 Average 90 stars, based on 1 article reviews
amg510 kras inhibitor - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
CH Instruments
amg 510 ![]() Amg 510, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/amg510/amg+510/pmc08894142-150-4-38 Average 90 stars, based on 1 article reviews
amg 510 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Frontiers in Cell and Developmental Biology
Article Title: A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness
doi: 10.3389/fcell.2021.665673
Figure Lengend Snippet: Benchmarking of top compound 1 in several cancer cell lines. (A) The relative 2D viability of various cell lines following single dose treatment with AMG-510 (1 μM), calmidazolium (2.5 μM), OphA (1 μM), and 1 (10 μM) was assessed using the alamarBlue assay. Cells were grown as 2D adherent monolayers overnight and then treated for 72 h with indicated compounds. Data represent mean values ± SD, n ≥ 3. (B) DSS 3 measuring the effects of AMG-510 (0.003–40 μM), calmidazolium (0.3–40 μM), OphA (0.3–40 μM), and 1 (0.6–80 μM). Cells were grown as 2D adherent monolayers overnight and then treated for 72 h. Results represent mean values ± SD, n = 3. (C) DSS 3 measuring the effects of AMG-510 (0.6–40 μM), vemurafenib (0.3–20 μM), prostratin (0.6–80 μM), OphA (0.3–20 μM), and 1 (1.3–80 μM). Cells were grown as 3D spheroids for 72 h then treated with compounds for another 72 h before alamarBlue viability measurements. Data represent mean values ± SD, n ≥ 2. (D) Heatmap of ATARiS gene sensitivity scores obtained from the project DRIVE database for KRAS-dependent cell lines (MIA PaCa-2, NCI H358, and MDA-MB-231) and HRAS-dependent cell lines (Hs 578T and T24). Negative values (red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, while positive (blue) indicates the opposite.
Article Snippet:
Techniques: Alamar Blue Assay, Knockdown
Journal: Communications Biology
Article Title: Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells
doi: 10.1038/s42003-026-10374-x
Figure Lengend Snippet: a Dose–response curves of MiaPaCa2 and H358 cells treated with sotorasib (Sot) or adagrasib (Ada) for 72 h, as determined by MTT assay. Data represent mean ± SD of triplicate wells. b Time-course of cell growth over 7 days under KRAS G12C inhibitor (30–1000 nM) treatment, as determined by MTT assay. Data represent mean ± SD of triplicate wells. c Schematic of the experimental workflow used to generate drug-tolerant (TR) cells. d Cell-cycle profiles of exponentially growing parental and TR cells.Representative raw histograms are displayed with the phases of the cell cycle (G 0 /G 1 , S, and G 2 /M). e Immunoblot analysis of mitogen-activated protein kinase (MAPK) and Akt pathway-related proteins in exponentially growing parental and TR cells. f Senescence-associated β-galactosidase (SA-β-gal) staining of exponentially growing parental and TR cells. Representative bright-field images are shown. Each dot represents one independent experiment, in which values have been averaged from three randomly selected fields per group. Data are presented as mean ± SEM from three independent experiments. Statistical significance was assessed by one-way ANOVA with Dunnett’s post hoc test; * P < 0.05, *** P < 0.001. Scale bar, 100 µm. g Proliferation recovery after drug withdrawal in TR cells. Parental and TR cells were seeded at 3 × 10 4 cells/cm 2 . TR cells were trypsinized and re-seeded, and proliferation was assessed under continued KRAS inhibition or after drug withdrawal (drug removal on day 0). Cell number was normalized to the Day 0 value for each condition. For conditions reaching confluence, the assay was terminated at the plateau time point. Data represent mean ± SD of triplicate wells. All experiments were independently repeated at least three times.
Article Snippet:
Techniques: MTT Assay, Western Blot, Analysis, Staining, Inhibition, FACS
Journal: Communications Biology
Article Title: Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells
doi: 10.1038/s42003-026-10374-x
Figure Lengend Snippet: a Schematic of the targeted inhibitor screening focusing on mitochondrial bioenergetic pathways. Compounds were selected to target key nodes in mitochondrial metabolism, including Tricarboxylic Acid (TCA)-cycle flux, electron transport chain activity, glutamine metabolism, and fatty acid oxidation. b Screening of small-molecule inhibitors targeting mitochondrial metabolism in MiaPaCa2-SotTR cells, as determined by ATP-based viability assay. Compounds and concentrations were as follows: malonate (10 µM), devimistat (100 µM), rotenone (1 µM), antimycin A (1 µM), epigallocatechin gallate (EGCG; 100 µM), CB-839 (10 µM), and etomoxir (50 µM). Cells were seeded at 3 × 10 4 cells/cm 2 . Data represent mean ± SD of triplicate wells. Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test; asterisks denote comparisons between the control and each compound on day 3, and hash marks denote comparisons between day 3 and day 6 for each compound; *** P < 0.001, ### P < 0.001. c Dose–response curves for EGCG in TR and parental cells. Cells were seeded at 3 × 10 4 cells/cm 2 . Cells were cultured in the presence or absence of 2 mM α-KG, and cell viability was assessed on day 9. Data represent mean ± SD of triplicate wells. d Time-course analysis of proliferation in TR cells treated with EGCG (100 µM) in the presence or absence of 2 mM α-KG, as determined by MTT assay. Cells were seeded at 3 × 10 4 cells/cm 2 . Data represent mean ± SD of triplicate wells. Statistical significance for the day 12 data was assessed by one-way ANOVA with Tukey’s post hoc test; *** P < 0.001. All experiments were independently repeated at least thrice.
Article Snippet:
Techniques: Screening, Activity Assay, Viability Assay, Control, Cell Culture, Analysis, MTT Assay, ATP Assay
Journal: Communications Biology
Article Title: Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells
doi: 10.1038/s42003-026-10374-x
Figure Lengend Snippet: a Schematic of time-course analysis of parental and TR cell proliferation. Parental and TR cells were seeded at 3 × 10 4 cells/cm 2 . b Time-course analysis of TR cell proliferation under glutamine-deprived conditions (Gln-), as determined by MTT assay. Data represent mean ± SD of triplicate wells. c Immunoblot analysis of LC3 levels in exponentially growing parental and SotTR cells treated with 5 μM chloroquine (CQ) for 4 h. d TR and parental cell number monitored over 12 days when cultured under glutamine-deprived conditions with or without CQ (15 μM), in the presence or absence of 2 mM α-ketoglutarate (α-KG), as determined by MTT assay. Data represent mean ± SD of triplicate wells. Statistical significance for the day 12 data was assessed by one-way ANOVA with Tukey’s post hoc test; *** P < 0.001. e TR and par e ntal cell number monitored over 12 days when treated with CB-839 (1 μM) with or without CQ (15 μM), in the presence or absence of 2 mM α-KG, as determined by MTT assay. Data represent mean ± SD of triplicate wells. Statistical significance for the day 12 data was assessed by one-way ANOVA with Tukey’s post hoc test; *** P < 0.001. f Immunoblot analysis o f glutaminase 1 (GLS1) levels in scramble control (Scr) and GLS1 knockout (KO) MiaPaCa2 cells. g Time-course analysis of cell number of Scr and GLS1 KO TR and parental cells treated with CQ (15 μM) in the presence or absence of 2 mM α-KG, as determined by MTT assay. Cells were seeded at 3 × 10 4 cells/cm 2 . Data represent mean ± SD of triplicate wells. Statistical significance at day 12 was assessed by one-way ANOVA with Tukey’s post hoc test; *** P < 0.001. All experiments were independently repeated at least three times.
Article Snippet:
Techniques: Analysis, MTT Assay, Western Blot, Cell Culture, Control, Knock-Out, Enzyme-linked Immunosorbent Assay
Journal: Communications Biology
Article Title: Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells
doi: 10.1038/s42003-026-10374-x
Figure Lengend Snippet: a Schematic of time-course analysis of TR cell proliferation. TR cells were seeded at 3 × 10 4 cells/cm 2 . b , c Number of TR cells when cultured under glutamine-deprived conditions ( b ) or treated with CB-839 (1 µM) ( c ) and chloroquine (CQ; 15 µM), with or without 2 mM α-ketoglutarate (α-KG) or 5 mM N-acetyl-L-cysteine (NAC) supplementation, as determined by MTT assay. Data represent mean ± SD of triplicate wells. Statistical significance for the day 12 data was assessed by one-way ANOVA with Tukey’s post hoc test; *** P < 0.001. d Fluorescence imaging of intracellular reactive oxygen species (ROS) in TR cells under combined glutamine deprivation and lysosomal inhibition. TR cells were cultured under glutamine-deprived conditions, treated with CQ (15 μM), or exposed to their combination in the presence or absence of α-KG (2 mM) for 6 days, as indicated. Representative images from three independent experiments are shown. Scale bar, 10 µm. Enlarged views are shown on the right. For each biological replicate, fluorescence values from individual cells were averaged to obtain a single value. Data represent mean ± SEM from three independent experiments (approximately five cells analyzed per replicate). Statistical significance was assessed by one-way ANOVA with Tukey’s post hoc test; * P < 0.05, ** P < 0.01, *** P < 0.001. e Cell-free assay to assess the ROS-suppressing (oxidant-buffering) activity of α-KG. Data represent mean ± SD of triplicate wells. Statistical analysis was performed on fluorescence values at 60 min using one-way ANOVA with Dunnett’s post hoc test; *** P < 0.001. All experiments were independently repeated at least thrice.
Article Snippet:
Techniques: Analysis, Cell Culture, MTT Assay, Fluorescence, Imaging, Inhibition, Cell-Free Assay, Activity Assay
Journal: The Journal of Experimental Medicine
Article Title: SHP2 inhibition diminishes KRAS G12C cycling and promotes tumor microenvironment remodeling
doi: 10.1084/jem.20201414
Figure Lengend Snippet: SHP2 inhibition enhances KRAS G12C -inhibitor effects in PDAC and NSCLC cell lines. (A) Cell viability was assessed by PrestoBlue assay at 6 d in Kras wt / KRAS G12C and Kras −/− / KRAS G12C MEFs. (B) Micrographs of spheroid cultures of KRAS G12C -expressing cells treated as indicated for 6 d. Numbers at left indicate KRAS G12C allele fraction. Scale bars, 1,000 µm. (C) Cell viability, assessed by PrestoBlue assay, at 0 and 6 d of MIAPaCa-2 spheroid cultures. (D) Schematic showing strategy used to generate the Lox- Kra s G12C allele from the pancreatic KCP 1203 cells, which carry a Lox- Kras G12D allele and a pancreas-specific Cre. KCP 1203 cells were cotransfected with a vector expressing Cas9 and a Kras -targeted sgRNA, together with a ssODN template bearing the new mutation. (E) PCR products using F1 + R2 primers to discriminate between mutant Kras (∼750 bp) and WT- Kras (∼720 bp) and C1 + R2 to detect the presence of the new G12C mutation in the KCP (G12C) clone, compared with parental KPC 1203 (G12D) cells. Primer forward F1 flanks the Lox region in intron 0, primer reverse R2 anneals the end of exon 1, and forward C1 specifically anneals on exon 1 in the presence of the new generated G12C mutation. (F) Sanger sequencing of TOPO-cloned PCR products (A–C in red) from E. (G) Allele-specific PCR using forward primers WT (W), G12D (D), and G12C (C) and reverse R2 in KCP G12C clone and parental KPC 1203 (G12D) cells. (H) Fragments per kilobase of exon per million reads mapped (FPKM) for Kras alleles in KCP cells. (I) Summary of genetic events that generated the new Lox- Kras G12C allele starting from parental KCP 1203 cells. (J) Cell death after 48 h of drug treatment, quantified by flow cytometry and Annexin V/7AAD staining (top), and immunoblot for cleaved PARP in lysates from MIAPaCa-2 and H358 cells, treated as indicated (bottom). (K) Viability of MIAPaCa-2 and H358 cells, assessed by PrestoBlue assay, after 6 d of treatment with DMSO, SHP099, AMG510 (0.1 µM) or COMBO. (L) PrestoBlue assays (6 d) on parental MIAPaCa-2 cells and PTPN11 -KO MIAPaCa-2 cells reconstituted with GFP or WT PTPN11 (WT). For all experiments, drug doses were SHP099 10 µM, ARS 10 µM, and AMG510 0.1 µM. Data represent mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; one-way ANOVA with Tukey’s multiple comparison test. Data represent average of at least three biological replicates with triplicate determinations of each point in each replicate. n.s., not significant; HR, homologous recombination; NHEJ, non-homologous end joining; R.F.U., relative fluorescence units.
Article Snippet: ARS and
Techniques: Inhibition, Prestoblue Assay, Expressing, Plasmid Preparation, Mutagenesis, Generated, Sequencing, Clone Assay, Flow Cytometry, Staining, Western Blot, Comparison, Homologous Recombination, Non-Homologous End Joining, Fluorescence
Journal: The Journal of Experimental Medicine
Article Title: SHP2 inhibition diminishes KRAS G12C cycling and promotes tumor microenvironment remodeling
doi: 10.1084/jem.20201414
Figure Lengend Snippet: SHP099 increases KRAS G12C -ARS adducts and acts upstream of RAS to block G12C-I–evoked ERK pathway reactivation. (A) 12C-ARS Fab binding to KRAS G12C with/without ARS and GTPγS or GDP. (B) Coomassie-stained SDS-PAGE of purified, recombinant KRAS G12C , preincubated with DMSO or ARS for 2 h. (C) Immunoblots of WCLs from H358 cells, treated with ARS for 2 h or left untreated, with or without incubation with calf-intestinal phosphatase (CIP). Note that CIP treatment eliminates the pERK signal but does not affect migration of KRAS, arguing against phosphorylation as the cause of the KRAS mobility shift. (D) Immunoblots of WCLs and 12C/V MB PDs from H358 and MIAPaCa-2 cells after treatment with DMSO, SHP099, AMG510, or COMBO, as indicated. For all experiments, drug doses were: SHP099 10 µM, ARS 10 µM, AMG510 0.1 µM. (E) Time-dependent increases in RTK (top) and RTK ligand (bottom) gene expression in KCP cells treated for 48 h with DMSO (CTRL), SHP099, ARS, or COMBO, as determined by RNA-seq (colors indicate log2FC). (F) ERK reactivation, as shown by immunoblot of lysates from MIAPaCa-2 cells treated with DMSO, ARS, or ARS + SHP099 (COMBO) for the indicated times. (G) ERK-dependent gene expression in KCP cells, as assessed by RNA-seq. (H–K) Immunoblots of WCLs and 12C/V MB PDs from KCP cells (H); H358 cells expressing DOX-inducible SOS1 shRNA (sh SOS ), ±DOX, as indicated (I); parental MIAPaCa-2 cells or MIAPaCa-2 cells PTPN11- KO expressing GFP or reconstituted with WT- PTPN11 , treated with ARS for 48 h (J); or MIAPaCa-2 cells expressing SHP099-resistant PTPN11 mutant (P491Q) or WT PTPN11 (WT) treated as described for the indicated times (K). (L) PrestoBlue assays, performed on PTPN11 -KO or PTPN11 -KO MIAPaCa-2 cells reconstituted with WT, C459E (CE), or Y542F + Y580F (2YF) PTPN11 , after 6 d of treatment with ARS or DMSO. For all experiments, drug doses were SHP099 10 µM or ARS 10 µM. Data represent mean ± SD; significance was assessed by multiple unpaired Student’s t test (two tailed). At least two biological replicates with triplicate determinations for each point in each replicate were performed. PAR, parental; R.F.U., relative fluorescence units.
Article Snippet: ARS and
Techniques: Blocking Assay, Binding Assay, Staining, SDS Page, Purification, Recombinant, Western Blot, Incubation, Migration, Phospho-proteomics, Mobility Shift, Gene Expression, RNA Sequencing, Expressing, shRNA, Mutagenesis, Two Tailed Test, Fluorescence
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Mass spectrometric identification and verification of an AMG510 covalently modified peptide from KRAS/G12C protein (A) MS/MS spectrum of the triply charged synthetic peptide (LVVVGACGVGK∗, ∗denote heavy isotope) covalently modified by AMG510 (left) and the extracted ion chromatograms (XICs) showing the retention times of free and modified peptides (right). Inset shows the precursor ion mass. (B) MS/MS spectrum of the AMG510-modified LVVVGACGVGK from trypsin digested recombinant KRAS/G12C protein (left) and XICs of the free and modified peptides (right).
Article Snippet: The
Techniques: Modification, Tandem Mass Spectroscopy, Recombinant
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Summary of the AMG510 modified proteins by direct profiling (A) AMG510 modified peptides with specific cysteine sites identified by direct profiling procedures: SDS-PAGE followed by in-gel digestion (In-Gel) or in-solution digestion followed by basic pH RP-LC (sRP). Two biological replicates are shown. Intensities are shown in log 10 transformed AMG510 modified peptides areas. (B) The time-dependence of the AMG510 modified KRAS/G12C peptide. The y axis on the left shows the intensity and the y axis on the right indicates the calculated target occupancy. (C) The dose-dependence of the AMG510 modified KRAS/G12C peptide. (D) A comparison of our method with previous studies on the number of off-targets modified by different covalent KRAS inhibitors.
Article Snippet: The
Techniques: Modification, SDS Page, Reversed-phase Chromatography, Transformation Assay, Comparison
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Enrichment and quantification of AMG510 modified peptides by using a pan anti-AMG510 antibody (A) Dot blot assay of the pan anti-AMG510 antibody on the unmodified LVVVGACGVGK peptide, or modified on the Cys12 by MRTX849 or AMG510. 100 ng of peptides or 10X serial diluted peptides were spotted on nitrocellulose membrane and detected with chemiluminescence. (B) A Venn diagram showing the reproducibility of the peptide-IP profiling of AMG510 modification sites in three biological replicates. (C) Scatterplots showing the Pearson correlation coefficients of modified peptide intensities between any two biological replicates on a log 2 scale. (D) Packcircles plot of peptide intensities of the off-targets identified in H358 cells treated with 2 μΜ AMG510 for 4h. The area of the circle and the color represents the relative intensities of each modified peptides. (E) Bioinformatics analysis of the prominent 197 AMG510 covalent protein targets in terms of cellular location. (F) The amino acid sequences flanking the AMG510 modified cysteine residue of the off-targets identified in (B) were analyzed by iceLogo.
Article Snippet: The
Techniques: Modification, Dot Blot, Membrane, Residue
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Temporal profiles of the off-targets identified in H358 cells (A) The 185 AMG510 off-targets are classified into 3 clusters based on the distinct kinetics of its members. (B) Heatmap of 45 differentially modified AMG510 off-targets identified in (A) and their associated biological pathways.
Article Snippet: The
Techniques: Modification
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: AMG510 off-targets identified in tissues of MIAPaCa-2 derived tumor xenograft Packcircles plot of intensities of off-targets from tumor (A) and heart tissue (C). The enriched pathways of the off-targets from tumor (B) and heart tissue (D) obtained from Metascape.
Article Snippet: The
Techniques: Derivative Assay
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: AMG510 modifies ALDOA and RAE1 and inhibits aldolase activity (A) Multiple cysteines in eight crucial glycolytic enzymes are modified by AMG510. (B) Structural view of AMG510 modified Cys339 in ALDOA (PDB: 4ALD ). The protein backbone is shown as slate cartoon. AMG510 is shown as cyan sticks and the fructose 1,6-bisphosphate is shown as deep salmon sticks. The distance between the two cysteines is shown. (C) Aldolase activity in H358 cells treated with 2μΜ AMG510 or vehicle control for 120 min. p values was calculated in Student’s t-tests performed on aldolase activity. Data are represented as mean ± SD. (D) Molecular docking modeling of the possible effect of AMG510 on the RAE1·NUP98 (PDB: 3MMY ) complex. Cys106 and NUP98 are colored in cyan and magenta, respectively.
Article Snippet: The
Techniques: Activity Assay, Modification, Control
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: AMG510 modifies Cys288 of KEAP1 and induces the nuclear accumulation of NRF2 in vivo (A) MS/MS spectrum of the AMG510-modified EILQSDSR from trypsin digested H358 cells after treatment with AMG510. (B) Western blotting showed the effect of AMG510 on the nuclear and cytoplasmic fraction of NRF2 protein of H358 cells. (C) Quantitative comparison of peptide-IP and western blot analysis on the activation of the covalent modification of KEAP1Cys288 and nuclear accumulation of NRF2. (D) Western blotting showed the effect of AMG510 on the nuclear of NRF2 protein of two NSCLC cell lines, including HCC827 (KRAS WT) and A549 (KRAS G12S).
Article Snippet: The
Techniques: In Vivo, Tandem Mass Spectroscopy, Modification, Western Blot, Comparison, Activation Assay
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet:
Article Snippet: The
Techniques: Recombinant, Activity Assay, Software
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Mass spectrometric identification and verification of an AMG510 covalently modified peptide from KRAS/G12C protein (A) MS/MS spectrum of the triply charged synthetic peptide (LVVVGACGVGK∗, ∗denote heavy isotope) covalently modified by AMG510 (left) and the extracted ion chromatograms (XICs) showing the retention times of free and modified peptides (right). Inset shows the precursor ion mass. (B) MS/MS spectrum of the AMG510-modified LVVVGACGVGK from trypsin digested recombinant KRAS/G12C protein (left) and XICs of the free and modified peptides (right).
Article Snippet:
Techniques: Modification, Tandem Mass Spectroscopy, Recombinant
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Summary of the AMG510 modified proteins by direct profiling (A) AMG510 modified peptides with specific cysteine sites identified by direct profiling procedures: SDS-PAGE followed by in-gel digestion (In-Gel) or in-solution digestion followed by basic pH RP-LC (sRP). Two biological replicates are shown. Intensities are shown in log 10 transformed AMG510 modified peptides areas. (B) The time-dependence of the AMG510 modified KRAS/G12C peptide. The y axis on the left shows the intensity and the y axis on the right indicates the calculated target occupancy. (C) The dose-dependence of the AMG510 modified KRAS/G12C peptide. (D) A comparison of our method with previous studies on the number of off-targets modified by different covalent KRAS inhibitors.
Article Snippet:
Techniques: Modification, SDS Page, Reversed-phase Chromatography, Transformation Assay, Comparison
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Enrichment and quantification of AMG510 modified peptides by using a pan anti-AMG510 antibody (A) Dot blot assay of the pan anti-AMG510 antibody on the unmodified LVVVGACGVGK peptide, or modified on the Cys12 by MRTX849 or AMG510. 100 ng of peptides or 10X serial diluted peptides were spotted on nitrocellulose membrane and detected with chemiluminescence. (B) A Venn diagram showing the reproducibility of the peptide-IP profiling of AMG510 modification sites in three biological replicates. (C) Scatterplots showing the Pearson correlation coefficients of modified peptide intensities between any two biological replicates on a log 2 scale. (D) Packcircles plot of peptide intensities of the off-targets identified in H358 cells treated with 2 μΜ AMG510 for 4h. The area of the circle and the color represents the relative intensities of each modified peptides. (E) Bioinformatics analysis of the prominent 197 AMG510 covalent protein targets in terms of cellular location. (F) The amino acid sequences flanking the AMG510 modified cysteine residue of the off-targets identified in (B) were analyzed by iceLogo.
Article Snippet:
Techniques: Modification, Dot Blot, Membrane, Residue
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: Temporal profiles of the off-targets identified in H358 cells (A) The 185 AMG510 off-targets are classified into 3 clusters based on the distinct kinetics of its members. (B) Heatmap of 45 differentially modified AMG510 off-targets identified in (A) and their associated biological pathways.
Article Snippet:
Techniques: Modification
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: AMG510 off-targets identified in tissues of MIAPaCa-2 derived tumor xenograft Packcircles plot of intensities of off-targets from tumor (A) and heart tissue (C). The enriched pathways of the off-targets from tumor (B) and heart tissue (D) obtained from Metascape.
Article Snippet:
Techniques: Derivative Assay
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: AMG510 modifies ALDOA and RAE1 and inhibits aldolase activity (A) Multiple cysteines in eight crucial glycolytic enzymes are modified by AMG510. (B) Structural view of AMG510 modified Cys339 in ALDOA (PDB: 4ALD ). The protein backbone is shown as slate cartoon. AMG510 is shown as cyan sticks and the fructose 1,6-bisphosphate is shown as deep salmon sticks. The distance between the two cysteines is shown. (C) Aldolase activity in H358 cells treated with 2μΜ AMG510 or vehicle control for 120 min. p values was calculated in Student’s t-tests performed on aldolase activity. Data are represented as mean ± SD. (D) Molecular docking modeling of the possible effect of AMG510 on the RAE1·NUP98 (PDB: 3MMY ) complex. Cys106 and NUP98 are colored in cyan and magenta, respectively.
Article Snippet:
Techniques: Activity Assay, Modification, Control
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet: AMG510 modifies Cys288 of KEAP1 and induces the nuclear accumulation of NRF2 in vivo (A) MS/MS spectrum of the AMG510-modified EILQSDSR from trypsin digested H358 cells after treatment with AMG510. (B) Western blotting showed the effect of AMG510 on the nuclear and cytoplasmic fraction of NRF2 protein of H358 cells. (C) Quantitative comparison of peptide-IP and western blot analysis on the activation of the covalent modification of KEAP1Cys288 and nuclear accumulation of NRF2. (D) Western blotting showed the effect of AMG510 on the nuclear of NRF2 protein of two NSCLC cell lines, including HCC827 (KRAS WT) and A549 (KRAS G12S).
Article Snippet:
Techniques: In Vivo, Tandem Mass Spectroscopy, Modification, Western Blot, Comparison, Activation Assay
Journal: iScience
Article Title: Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target
doi: 10.1016/j.isci.2023.106080
Figure Lengend Snippet:
Article Snippet:
Techniques: Recombinant, Activity Assay, Software